TY - JOUR
T1 - The effect of recombinant interleukin-10/Fc fusion protein on lipopolysaccharide-induced acute lung injury in mice
AU - Bi, Ming Hua
AU - Wang, Bao En
AU - Zheng, Xin Xiao
AU - Li, Min
AU - Mayer, Konstantin
AU - Zhang, Shu Wen
PY - 2008/8/10
Y1 - 2008/8/10
N2 - Objective: To clarify the regulatory role and mechanism of recombinant interleukin-10/Fc (rIL-10/Fc) fusion protein on inflammatory parameters during development of acute lung injury (ALI) induced by lipopolysaccharide (LPS) in a murine model. Methods: An ALI model was reproduced by intra-tracheal injection of LPS. rIL-10/Fc was administered intraperitonealy. One hundred and thirty-two BALB/c mice were divided into four groups, including saline control group, rIL-10/Fc control group, ALI model group, and rIL-10/Fc treatment group. Twenty-four-hour survival rate was determined in 25 mice of each group. The number of inflammatory cells and inflammatory mediators in bronchia-alveolar lavage fluid (BALF), tumor necrosis factor-α (TNF-α) and IL-1β, and also lung myeloperoxidase (MPO) activity, lung wet/dry (W/D) ratio were determined in the rest of mice. Pathological changes in lung were examined with hematoxylin-eosin (HE) staining, and inflammatory change was evaluated under microscope. Results: Levels of TNF-α and IL-1β in BALF were substantially increased 4 hours after intra-tracheal LPS (both P< 0.01), and they were lowered but without significant difference after rIL-10/Fc administration. However, rIL-10/Fc fusion protein markedly attenuated release of TNF-α at 8 hours and 12 hours, and IL-1β was lowered at 12 hours after LPS challenge. Pre-treatment with rIL-10/Fc fusion protein significantly improved survival rate at 24 hours in LPS challenged mice (P<0.01). There was no significant difference in cell count in BALF, MPO, lung W/D ratio, after treatment of rIL-10/Fc fusion protein. Obvious inflammatory changes were found in lung was found pathologically at 24 hours after LPS injection, but there was no significant difference compared with ALI mice with rIL-10/Fc fusion protein administration. Conclusion: rIL-10/Fc fusion protein inhibits release of TNF-α and IL-1β in BALF in a LPS-induced ALI routine model. rIL-10/Fc fusion protein improves survival rate in ALI mice by decreasing the release of pro-inflammatory cytokines.
AB - Objective: To clarify the regulatory role and mechanism of recombinant interleukin-10/Fc (rIL-10/Fc) fusion protein on inflammatory parameters during development of acute lung injury (ALI) induced by lipopolysaccharide (LPS) in a murine model. Methods: An ALI model was reproduced by intra-tracheal injection of LPS. rIL-10/Fc was administered intraperitonealy. One hundred and thirty-two BALB/c mice were divided into four groups, including saline control group, rIL-10/Fc control group, ALI model group, and rIL-10/Fc treatment group. Twenty-four-hour survival rate was determined in 25 mice of each group. The number of inflammatory cells and inflammatory mediators in bronchia-alveolar lavage fluid (BALF), tumor necrosis factor-α (TNF-α) and IL-1β, and also lung myeloperoxidase (MPO) activity, lung wet/dry (W/D) ratio were determined in the rest of mice. Pathological changes in lung were examined with hematoxylin-eosin (HE) staining, and inflammatory change was evaluated under microscope. Results: Levels of TNF-α and IL-1β in BALF were substantially increased 4 hours after intra-tracheal LPS (both P< 0.01), and they were lowered but without significant difference after rIL-10/Fc administration. However, rIL-10/Fc fusion protein markedly attenuated release of TNF-α at 8 hours and 12 hours, and IL-1β was lowered at 12 hours after LPS challenge. Pre-treatment with rIL-10/Fc fusion protein significantly improved survival rate at 24 hours in LPS challenged mice (P<0.01). There was no significant difference in cell count in BALF, MPO, lung W/D ratio, after treatment of rIL-10/Fc fusion protein. Obvious inflammatory changes were found in lung was found pathologically at 24 hours after LPS injection, but there was no significant difference compared with ALI mice with rIL-10/Fc fusion protein administration. Conclusion: rIL-10/Fc fusion protein inhibits release of TNF-α and IL-1β in BALF in a LPS-induced ALI routine model. rIL-10/Fc fusion protein improves survival rate in ALI mice by decreasing the release of pro-inflammatory cytokines.
KW - Acute lung injury
KW - Lipopolysaccharide
KW - Recombinant interleukin-10/Fc fusion protein
UR - http://www.scopus.com/inward/record.url?scp=51349085446&partnerID=8YFLogxK
M3 - Article
C2 - 18687171
AN - SCOPUS:51349085446
SN - 1003-0603
VL - 20
SP - 461
EP - 464
JO - Chinese Critical Care Medicine
JF - Chinese Critical Care Medicine
IS - 8
ER -